HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

M T Lotze Selected Research

Neoplasms (Cancer)

10/2016First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.
6/2015The receptor for advanced glycation end products (RAGE) enhances autophagy and neutrophil extracellular traps in pancreatic cancer.
3/2015You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia.
10/2014RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer.
1/2014The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics.
12/2013Strange attractors: DAMPs and autophagy link tumor cell death and immunity.
4/2011The Beclin 1 network regulates autophagy and apoptosis.
1/2011HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells.
9/2010HMGB1 release and redox regulates autophagy and apoptosis in cancer cells.
4/2010The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


M T Lotze Research Topics

Disease

31Neoplasms (Cancer)
10/2016 - 02/2000
4Glioma (Gliomas)
08/2001 - 03/2000
3Melanoma (Melanoma, Malignant)
12/2019 - 02/2000
3Pancreatic Neoplasms (Pancreatic Cancer)
06/2015 - 01/2005
3Gliosarcoma
08/2001 - 05/2000
3Neoplasm Metastasis (Metastasis)
04/2001 - 02/2000
3Central Nervous System Neoplasms
03/2001 - 03/2000
2Leukemia
03/2015 - 01/2011
2Squamous Cell Carcinoma (Epidermoid Carcinoma)
08/2001 - 04/2000
2Neuroblastoma
08/2001 - 01/2001
1Hyperglycemia
10/2016
1Lymphoma (Lymphomas)
10/2016
1Non-Hodgkin Lymphoma (Lymphosarcoma)
10/2016
1Atrophy
05/2015
1Cognitive Dysfunction
05/2015
1Cerebrovascular Disorders (Cerebrovascular Occlusion)
05/2015
1Carcinogenesis
04/2011
1Inflammation (Inflammations)
04/2010
1Chronic Pancreatitis
01/2005
1Experimental Melanoma
10/2001
1Fibrosarcoma
10/2001
1Breast Neoplasms (Breast Cancer)
01/2001
1Nasopharyngeal Carcinoma
01/2001
1Pancytopenia
01/2001
1Sarcoma (Soft Tissue Sarcoma)
09/2000
1Prostatic Neoplasms (Prostate Cancer)
08/2000

Drug/Important Bio-Agent (IBA)

8Interleukin-12 (IL 12)IBA
08/2001 - 02/2000
7CytokinesIBA
01/2005 - 02/2000
6Interleukin-2 (IL2)IBA
12/2019 - 02/2000
6Proteins (Proteins, Gene)FDA Link
05/2015 - 02/2000
5Receptor for Advanced Glycation End ProductsIBA
06/2015 - 04/2010
5Interleukin-4 (Interleukin 4)IBA
08/2001 - 03/2000
4HMGB1 Protein (HMG1)IBA
01/2014 - 04/2010
3DNA (Deoxyribonucleic Acid)IBA
06/2015 - 04/2000
3LigandsIBA
01/2014 - 04/2000
3Peptides (Polypeptides)IBA
10/2001 - 02/2000
3Cancer VaccinesIBA
04/2001 - 03/2000
2Biomarkers (Surrogate Marker)IBA
05/2015 - 01/2005
2Paclitaxel (Taxol)FDA LinkGeneric
09/2010 - 04/2000
2NF-kappa B (NF-kB)IBA
04/2010 - 10/2001
2Interleukin-18 (Interleukin 18)IBA
11/2002 - 09/2000
2AntigensIBA
08/2001 - 03/2001
2Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
08/2001 - 04/2000
2VaccinesIBA
04/2001 - 03/2000
2InterleukinsIBA
09/2000 - 02/2000
1Immune Checkpoint InhibitorsIBA
12/2019
1copanlisibIBA
10/2016
1Class I Phosphatidylinositol 3-KinasesIBA
10/2016
1Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
10/2016
1Histones (Histone)IBA
06/2015
1Amyloid (Amyloid Fibrils)IBA
05/2015
1LipidsIBA
05/2015
1Biological ProductsIBA
05/2015
1Hydroxychloroquine (Plaquenil)FDA LinkGeneric
03/2015
1Hypoxia-Inducible Factor 1IBA
10/2014
1Adenosine Triphosphate (ATP)IBA
01/2014
1Death Domain ReceptorsIBA
04/2011
1Beclin-1IBA
04/2011
1Pharmaceutical PreparationsIBA
01/2011
1AntibodiesIBA
01/2011
1Intercalating AgentsIBA
09/2010
1Toll-Like Receptor 4IBA
09/2010
1ethyl pyruvateIBA
09/2010
1Alkylating AgentsIBA
09/2010
1TubulinIBA
09/2010
1Small Interfering RNA (siRNA)IBA
09/2010
1Doxorubicin (Adriamycin)FDA LinkGeneric
09/2010
1Antineoplastic Agents (Antineoplastics)IBA
09/2010
1Oxaliplatin (Eloxatin)FDA LinkGeneric
09/2010
1Melphalan (Alkeran)FDA LinkGeneric
09/2010
1CarcinogensIBA
04/2010
1ChemokinesIBA
01/2005
1RV 538 (PDMP)IBA
10/2001
1ceramide glucosyltransferaseIBA
10/2001
1Cycloserine (Seromycin)FDA Link
10/2001
1Phorbol EstersIBA
10/2001
1N-oleoylethanolamineIBA
10/2001
1CeramidesIBA
10/2001
1Interleukin-10 (Interleukin 10)IBA
10/2001
1Acid CeramidaseIBA
10/2001
1Interferon-alpha (Interferon Alfa)IBA
08/2001
1Interferon-gamma (Interferon, gamma)IBA
08/2001
1Neoplasm Antigens (Tumor Antigens)IBA
08/2001
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
04/2001
1Monoclonal AntibodiesIBA
04/2001
1S100 Calcium Binding Protein A6IBA
03/2001
1Complementary DNA (cDNA)IBA
03/2001
1monoaminocarboxydihydroboraneIBA
01/2001
1GangliosidesIBA
01/2001
1Interleukin-15 (Interleukin 15)IBA
08/2000
1Apoptosis Regulatory ProteinsIBA
08/2000
1CD40 Ligand (CD40L)IBA
08/2000
1salicylhydroxamic acid (SHAM)IBA
05/2000

Therapy/Procedure

12Therapeutics
12/2019 - 02/2000
6Immunotherapy
08/2001 - 02/2000
4Drug Therapy (Chemotherapy)
12/2019 - 01/2011
1Cell- and Tissue-Based Therapy (Cell Therapy)
12/2019
1Injections
04/2001
1Intra-Arterial Injections
01/2001
1Immunomodulation
05/2000